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against multiple SARS-CoV-2 antigens in a cohort
of patients presenting with COVID-19 syndrome†
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An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG anti-
body concentrations against spike 1 (S1), spike 2 (S) and nucleocapsid (N) was conducted using serum
samples from 74 patients tested for SARS-CoV-2 RNA on admission to hospital, and 47 historical control
patients from March 2019. 59 patients were RNA(+) and 15 were RNA(−). A serum (±) classification was
derived for all three antigens and a quantitative serological profile was obtained. Serum(+) was identified
in 30% (95% CI 11–48) of initially RNA(−) patients, in 36% (95% CI 17–54) of RNA(+) patients before 10
days, 77% (95% CI 67–87) between 10 and 20 days and 95% (95% CI 86–100) after 21 days. The patient-
level diagnostic accuracy relative to RNA(±) after 10 days displayed 88% sensitivity (95% CI 75–95) and
75% specificity (95% CI 22–99), although specificity compared with historical controls was 100% (95%CI
91–100). This study provides robust support for further evaluation and validation of this novel technology
in a clinical setting and highlights challenges inherent in assessment of serological tests for an emerging
disease such as COVID-19.
Introduction
Coronaviruses cause disease in birds and mammals1,2 and
usually cause mild respiratory diseases in humans; however,
strains have emerged such as SARS and MERS causing out-
breaks of lethal respiratory disease1 and in December 2019 a
novel coronavirus was identified in Wuhan, China. The causa-
tive agent named SARS-CoV-2 causes coronavirus disease 2019
(COVID-19) and has led to a global pandemic.
Patients presenting to hospital with clinical and radiologi-
cal features consistent with COVID-disease usually have a
SARS-CoV-2 RNA PCR test performed on upper respiratory
tract specimens (e.g. nose and throat swabs) to confirm the
diagnosis. Throughout this paper we refer to positive results as
RNA(+) and negative as RNA(−). The reliability of PCR swabs
are subject to pre-analytical errors such as the quality of
sample collection, the technology platform and the primers
designed, and for clinical reasons such as infection being loca-
lised to the lower respiratory tract.3 Some patients also present
late when the viral infection may have passed when symptoms
may predominantly be due to immunological, inflammatory
and thrombotic processes.4 Comparisons between clinical,
radiological and PCR findings illustrate these challenges. In
one study 35% of patients with positive CT scan findings were
admission RNA(−). Review of serial CT images and clinical
findings showed 17% and 12% of admission RNA(−) patients
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were finally given a COVID-19 diagnosis, and 93% became
RNA(+) after further testing over 5 days.3 These observations
illustrate the benefit of aggregating information from multiple
sources to support the clinical diagnosis from which the many
management decisions can take place.
SARS-CoV-2 infection stimulates an antigen specific anti-
body response. Detecting these antibodies has potential to
provide diagnostic information, even though serology is not
conventionally used for diagnosis of acute respiratory viral
infection such as influenza. Serology may also have a role in
population screening, modelling disease spread in the com-
munity and staff surveillance, and there may be different
required performance criteria in these different settings. There
have been a number of reports describing SARS-CoV-2 anti-
body detection methodologies and technologies, including
ELISA assays and lateral flow devices. None is currently con-
sidered to have acceptable sensitivity or specificity for
diagnosis.5
Here we present a detailed evaluation of a novel gold nano-
particle array technology that provides a quantitative multi-
plexed 9-dimensional measure of the IgG, IgA and IgM
response to SARS-CoV-2 S1, S2 and N proteins. The study was
performed using a pre-determined set of samples obtained
from a real-world cohort of patients admitted to St Thomas’
Hospital with a suspected clinical diagnosis of COVID-19 on
admission and in whom a SARS-CoV-2 RNA PCR was per-
formed. The results of the multiplexed response profile were
related to RNA(±) patient classification and time. This robust
initial analysis supports proceeding to validation of this
technology as a potential serological technology solution for
addressing key needs in response to the SARS-CoV-2
pandemic.
Experimental methods
Multiplexed COVID-19 antigen array and liscar reader
The tests were performed on the portable bench-top multi-
plexed array technology that has been described in detail
elsewhere.6–10 It has been shown effective at detecting anti-
body in response to vaccination11 and has characterised accu-
racy and precision for CRP and total IgG assays6 with typically
10% accuracy and intra-day precision of less than 5%. The
technology consists of an array of 170 of gold nanoparticle
spots which scatter light into a video camera when illuminated
from below (Fig. S1†). Each array includes antibody to capture
CRP, Protein A/G to capture total Fc-binding antibodies and
COVID-19 recombinant antigens S1, S2, and N protein along
with SARS membrane (M) and envelope (E) proteins.
Diluted serum (or whole blood) is injected into the device
to flow over the array producing a brightness change time
(Fig. 1) during a loading step, before undergoing a wash cycle.
A detection anti-CRP completes a sandwich assay for the CRP
assay and an antibody recognising all human IgG, IgM and IgA
detects total serum antibodies binding to each SARS CoV2
antigen (the Rapid Test). Alternatively, antibodies specific to
IgG, IgM and IgA in series can be applied to detect individual
responses to determine specific IgG, IgM and IgA against each
antigen (The Antibody Class Differential Test). The light inten-
sity change in the detection step is integrated for two minutes
to produce an area under the curve (AUC) of light intensity
seconds (Fig. 1). The test cycle takes 7.5 minutes followed by
2.5-minute regeneration.
Array biofunctionalisation and materials
The arrays were functionalised according to the procedure
detailed elsehwhere.6 Briefly, the antigens S1, S2, E/M antigens
were printed as received from the supplier onto the gold
surface functionalised with EDC/NHS. The N antigen was
buffer exchanged prior to printing into the standard PBS/gly-
cerol buffer. The arrays were washed and blocked with serum
at stored at 4 °C prior to use.
The materials used in the course of the experiments were
used without further purification, as certified by the suppliers.
Sigma-Aldrich supplied phosphate buffered saline in tablet
form (Sigma, P4417), phosphoric acid solution (85 ± 1 wt% in
water, Sigma 345245), Tween 20 (Sigma, P1379), N-(3-dimethyl-
aminopropyl)-N′-ethylcarbodiimide hydrochloride (commercial
grade, E7750), N-hydroxysuccinimide (98%, 130 672) and
bovine serum albumin (>98%, A3059). SAM molecules, linker
HS-C11-EG6-OCH2-COOH (>95%, TH 003-M11.N6) and spacer
HS-C11-EG3-OH (>95%, TH 001-M11.N3), were supplied by
ProChimia Surfaces. Native human C-reactive protein (>99%,
P100-0) and CRP depleted serum (SF100-2) were obtained from
BBI Solutions. Glycine (analytical grade, G/0800/48) was pro-
vided by Fisher Scientific and recombinant PAG (21186) was
supplied by ThermoFisher Scientific. The assay running and
dilution buffer was PBS with 0.005 v/v % Tween 20 and the
regeneration buffer was 0.1 M phosphoric acid and 0.1 M
glycine solution in deionized water.
The recombinant antigens REC31754-100 SARS Coronavirus
Envelope Protein (E. coli); REC31753-100 SARS Coronavirus
Membrane Protein (Matrix) (E. coli); REC31806-100
SARS-CoV-2 Spike Glycoprotein (S1), SHFc-Tag (HEK293);
REC31807-100 SARS-CoV-2 Spike Glycoprotein (S2), SHFc-Tag
(HEK293); REC31812-100 SARS-CoV-2 Nucleoprotein His-Tag
(E. coli); and PAB21446 Rabbit Anti-Sheep (H + L) were sup-
plied by the Native Antigen Company (Oxford). SAB3700698
Anti-Sheep IgG (Fc specific) polyclonal Antibody produce in
rabbit, sourced from Sigma-Aldrich.
Detection reagents were supplied by Bio-Rad, 5211-8004
Goat Anti-Human IgG polyclonal Antibody, STAR141 Goat
Anti-Human IgA polyclonal Antibody, STAR145 Goat Anti-
Human IgM polyclonal Antibody, STAR 125 Goat Anti-Human
IgG polyclonal Antibody, 1707-0189G goat anti human CRP
polyclonal antibody; and Randox: IA8354
Immunoturbidimetric Anti-Human IgA Antibody, IG8352
Immunoturbidimetric Anti-Human IgG Antibody, IM8353
Immunoturbidimetric Anti-Human IgM Antibody.
A serum negative standard, CRP depleted serum (BBI
SF100-2) acting as CRP(−) control and a SARS-COV-2 antibody
negative control. Similarly, a CRP positive control (Level 3
Paper Analyst
























































































Randox CP2481) is a SARS-COV-2 antibody negative control. A
positive patient control was identified early in testing and used
as part of the QC process.
Array test protocol
COVID-19 chips are calibrated using the CRP assay referenced
to the WHO CRP standard material. A calibration curve for
CRP has a lower limit of detection of 1 mg L−1 and a dynamic
range to 150 mg L−1.6 The total antibody assay is calibrated
using the NIST standard antibody to determine the absolute
surface binding site density. Only the CRP and PAG assays can
be calibrated absolutely as standard reference materials are
available; no reference materials were available for the antigen
antibodies at the time of data collection. The surface antigen
channels are calibrated by an antibody raised to sheep Fc
region synthesised on the recombinant S1 and S2 antigens or
a poly-his-tag synthesised on the recombinant membrane
antigen for purification. The tags are used or affinity purifi-
cation but can also be used to determine the antigen binding
site density on the surface which can be used to predict the
calibration curve but allows the relative intensities to be esti-
mated (semi) quantitatively. The error in the calibration
process predicted from binding site density is associated with
non-specific binding. The mean coefficient of variation across
repeats with the same sample performed on the same arrays
without any correction were S1, 7.8%, S2 19.2%, N 7.8%, CRP,
10% and Total IgG 1.5%. The Limit of Blank was 0.186 ± 0.07
(mean ± standard deviation) compared with the N(+) cut-off of
0.31.
A dilution study was performed on a positive patient to
establish the antibody titre and CRP concentration (Fig. S2†).
It shows that neither assay is saturated indicating a significant
dynamic range and the samples with the 100-fold initial
dilution are well placed on the calibration curve. Antibody titre
is used as a measure of concentration when reference
materials are not available; an n-fold dilution of a sample is
Fig. 1 (A) Time course of the simultaneous evolving sensor response for each antigen in real time for a representative RNA(+) patient showing the
combined IgM, IgG, and IgA response against membrane (Mem), spike (S) 1 and 2, nucleocapsid (N) and envelope (Env), and host proteins aCRP, total
IgG (represented as the capture antigen Protein A/G (PAG)). The first set of responses (before 250 seconds) shows binding in response to patient
serum exposure and the second set of responses the detection antibody (300–400 seconds) (B) The combined IgG, IgA and IgM sensor response in
mRIU seconds is shown for each viral and host antigen integrated over 120 seconds. The total serum IgG level (represented as PAG in (A) is divided
by 5 (C) Evolution of the IgM, IgG and IgA response for a single patient.
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performed until the signal falls below the detection limit.
Relative concentration can then be determined from dilution
and absolute concentrations by determining the titres from
the NIST reference antibody of WHO CRP reference materials.
for all antibody titres. The N antibody titre is 1/6700–1/10 000
compared with the CRP at 300 mg L−1 with titre 1/1000.
Patient testing was performed under batch control with two
refractive index standards to calibrate the brightness change, a
serum negative standard, a CRP positive standard and a posi-
tive patient standard repeated every 20 patients (Fig. S2†).
Degradation of the antigen chip was recorded for each batch
under standardised conditions and varied between patient
samples applied allowing between 30–50 sample runs per chip
before replacement. Chip-to-chip variation was normalised
using control samples.
Study design
As a first assessment of the device clinical validity amongst
hospitalized patients, the design was initially conceptualised
as a two-gate diagnostic accuracy study12 of test performance
in detecting COVID-19 infection, as defined by a positive
SARS-CoV-2 RNA PCR swab during that admission. However,
the design had to be modified to acknowledge that while a
positive PCR test strongly indicates the presence of COVID-19
disease, a negative result is weakly indicative of the absence of
disease because of well documented and theoretically plaus-
ible false negative PCR test results in a significant minority of
patients. Further, index test negativity in PCR positive patients
might be expected in patients in the early stage of disease
before antibodies are produced or in patients who could not
mounting an antibody for whatever reason. We thus focused
on descriptively reporting findings of the index test in the
patient sample series. We considered results at a sample level
and a patient level, particularly evolution of results over time.
Viral RNA positivity or negativity at any stage during admis-
sion was retained as an important explanatory variable for
results, alongside others, and percentage agreement calculated
with 95% confidence intervals.13 Although these can be con-
sidered as early estimates of accuracy (sensitivity and speci-
ficity), great caution is required in their interpretation because
of the underlying uncertainty about the true disease state, par-
ticularly absence of disease. Specificity is thus affected more
than sensitivity. In order to avoid bias from setting cut-offs for
index test positivity using the same samples as those used for
evaluating accuracy, we initially separated samples into Phase
1 (training set) and Phase 2 (evaluation set). Phase 3 was
further added using new samples not examined in Phases 1
and 2, to specifically improve the precision of our “sensitivity”
estimate. The size of this was informed by a target sample size
estimation of 45 patients assuming a true value of 100% and a
lower 95% CI of 90%. The measurement of specificity relative
to stored samples before the start of the COVID pandemic con-
stituted a fourth phase of the investigation. The size of this
was again informed by a sample size estimation of 45 patients
assuming a true value of 100% and a lower 95% CI of 90%.
Finally, to specifically extend the patient antibody profiles,
additional specimens for these patients were purposively
sought. These were not included in the analyses of any other
phases. For the patient level analysis, where there are multiple
samples for the patient, a summary value was calculated as the
mean of the sample values, having first confirmed that there
was consistency between the values, which was true in all
patients. The results were reported according to the STARD
reporting framework as the most relevant guideline for the
study design undertaken.14
Patient and sample origin
The cohort comprised patients admitted to St Thomas’
Hospital with suspected COVID-19 between February 27th and
March 30th 2020 and on whom a SARS-CoV-2 RNA PCR test
was performed. Surplus serum was retrieved from the routine
biochemistry laboratory at point of discard, and then ali-
quoted, stored and linked with a limited clinical dataset by the
direct care team, before anonymization under an existing
ethics framework (REC reference 18/NW/0584) and with expe-
dited R&D approval. Members of the research team conducting
serology testing only had access to anonymised clinical infor-
mation during the duration of the study. For Phases 1 and 2,
although viral RNA status was known, no further clinical
details were available to the analysing team prior to the device
results being obtained. In Phase 3, viral RNA status and time
of sample relative to symptom onset were known. Where the
same patient contributed to multiple phases, it was with a
different sample. 47 anonymised serum samples stored in
March 2019 from patients who did not have had SARS-CoV2
infection stored for future technology evaluation projects
under the same ethical approval as above, were used as a
control cohort. The complete dataset will be fully anonymised
at the end of the study period. All work was performed in
accordance with the UK Policy Framework for Health and
Social Care Research, and approved by the Risk and Assurance
Committee at Guy’s and St Thomas’ NHS Foundation Trust.
Informed consents were not required from participants in this
study as per the guidelines set out in the UK Policy Framework
for Health and Social Care Research and by the registration
with and express consent of the Institutional Review Board
listed above.
Results
Patient and sample cohorts
Summary characteristics of all 119 samples used for the first 3
study phases collected from 74 patients admitted between 21/
02/20 and 30/3/20 and tested for SARS-CoV-2 are summarised
in Table 1. Distribution of samples and patients within each
phase is shown in Table S1.† Where the same patient contribu-
ted to multiple phases, it was with a different sample. The
cohort was typical of COVID-19 patients admitted to hospitals
around the world with 27 patients admitted to the intensive
care unit during their admission, and there had been 10
deaths and 25 patients discharged home as at 30/3/20.
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Recorded co-morbidities, outcomes and level of support for
each patient linked with each serum sample is presented in
Tables S1–3.† A statistically determined set of 47 stored serum
samples from patients presenting to A&E before the start of
the pandemic were used as a further control cohort.
Sample level analysis
Serum antibody testing against all antigens was evaluated on a
single batch production of 6 COVID-19 chips each normalised
for their refractive index sensitivity. A typical sensor response
profile for each viral antigen and host protein (CRP and total
IgG) is shown in Fig. 1(A) The combined IgG, IgA and IgM
response against each viral antigen is shown in Fig. 1(B). The
dominant combined IgM, IgA and IgG response is consistently
observed against N with a range 100–300 mg L−1 for the
samples tested. Individual quantitative IgM, IgA and IgG
responses to each antigen were performed for a number of
patients to determine the evolution of the differential IgM, IgG
and IgA response over time, shown as a time course for one
patient (Fig. 1C).
The combined IgM, IgA and IgG antibody response against
N was taken forward as the serological response marker for
SARS CoV-2 infection due to it having the highest quantitative
response. The N antibody level detected in all 119 serum
samples plotted against time from patient-reported first day of
symptom onset is shown in Fig. 2. A sample classification was
set at <10 days consistent with reported onset of serological
response.15 Two serum samples taken from patients with <10
days of reported symptoms had high antibodies against
N. Clinical data provided to the laboratory team were reviewed.
The upper red circled data point is from a patient admitted
with a differential diagnosis of community-acquired pneumo-
nia. They had a negative SARS-CoV-2 nose and throat PCR per-
formed on day 10 and day 18 of symptom onset and a negative
PCR on a bronchoalveolar lavage taken on Day 21 while on
ITU. The lower red circled data point was from a patient who
had dementia and so the first day of symptom onset of interval
may be incorrect.
A time-course of the antibody response against N was
plotted for 9 patients using serum samples taken between
symptom-day 9 and 45 (Fig. 3). This included serum samples
provided from patients who remained in hospital beyond the
end of the study period. One patient who died on Day 15 had
negative N antibody measurements in 4 serum samples taken
daily between day 11 and 15.
Table 1 Summary patient cohort clinical characteristics
Cohort size 74
Age mean (SD) 55.3 (16.7)
Male 50 (68%)
No comorbidity 10 (14%)
Multiple comorbidities 48 (65%)
Mortality 10 (14%)
Discharged at time of analysis 21 (28%)
Median LOS not died or discharged (to 30/3/20) (range) 14 (0 to 38)
Required mechanical ventilation 38 (51%)
Required no respiratory support 14 (19%)
Viral RNA positive at any stage 59 (80%)
Single sample 61 (82%)
Multiple samples 13 (18%)
Mean number of samples where multiple 3.8
LOS, length of stay. Data was extracted from clinical records by the
clinical care team prior to sample anonymisation.
Fig. 2 Distribution of total antibody response to N antigen (mRUI
seconds) plotted against time from first day of patient reported
symptom onset recorded by the admitting patients care team. Serum
total antibody levels against the N antigen recorded from patients who
had died at the end of the study period are identified with a black square
(as of 30/3/20).
Fig. 3 Time course of the antibody response against NC plotted over
time for 9 patients during their hospital stay. Additional data points were
added through analysis of serum samples provided by the clinical care
team for patients who remained in hospital beyond the end of the study
period.
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Classification of a serum sample being either S1, S2 or N
antibody positive was made based on RNA(−) phase 1 samples
from which cut-off levels for each viral antigen were derived
(see Methods). The antibody levels against S1, S2 and N for all
samples taken from RNA(−) and RNA(+) patients with their
respective cut-offs presented as horizontal black lines are
shown in Fig. 4. A Boolean classifier of being S1(+) or S2(+) or
N(+) was used to classify patients as seropositive, rather than
using N antibody response data alone as presented in Fig. 2
and 3 (Table 2). Using this classification 7(30%) of RNA(−)
samples had serum(+) antibody concentrations above the cut
off for all three viral antigens (triple RNA(−) false negative).
The triple classification assessment identified 22% of all
serum positive samples as S1(+) S2(−) N(+), 51% S1(−) S2(+)
and N(+) and 18% S1(+) S2(+) and N(+).
Classifications of all samples tested in phase 1, 2 and 3 are
shown in Table 2 and show a 79% (95% CI 71–97) serum anti-
body positive rate for the whole clinically heterogenous cohort
at all time intervals including the slow-response and patients
who died early and those that did not appear to show an anti-
body response over time. The positivity rate varied by interval
from day of first symptom onset with maximum sensitivity of
95% (95% CI 71–97) being observed at 21 days. Finally, a
further 47 randomly selected anonymised serum samples from
Table 2 Sample serum classification table using three-antigen Boolean classifier
Serum (+) Serum (−) Total Serum (+) percentage
RNA(−) 7 16 23 30% (95% CI 11–48)
RNA(+) all intervals 76 20 96 79% (95% CI 71–97)
Total 83 36 119
Interval samples
RNA(+) < 10 days 9 16 25 36% (95% CI 17–54)
RNA(+) 10–20 days 53 16 69 77% (95% CI 67–87)
RNA(+) > 21 days 21 2 23 95% (95% CI 86–100)
Total 83 34 117a
a Time interval not available for two patients.
Fig. 4 Antigen response for S1(3×), S2 (3×) and N response for RNA(−) and RNA(+) patients in the cohort. The RNA(−) shows outliers in all three
antigen distributions and the cut-off is set at the highest value in the distribution (line). The RNA(+) patient group has varying intervals from onset of
symptoms with varying rates of recovery. There is a set of patients who have not yet responded or not going to respond (below the cut-off line) that
correspond to the early-time patients below 10 days shown in Fig. 1. These are excluded in the recovering +10 days cohort. The biobank data set is
included for the specificity analysis.
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the diagnostic laboratory taken during March 2019 were pro-
vided by the clinical team for analysis, and all were serum(−)
for all three antibodies against all three viral protein targets
(Fig. 4).
Patient level analysis
The patient-level analysis initially focused on the 24 patients
evaluated in the second phase of testing. Using thresholds
derived from the first phase of testing for S1(+) 0.10
(16 mRIUs), S2(+) 0.05 (8 mRIUs) and N(+) 0.31 (47 mRIUs),
the sensitivity based on being (+) for any one antigen was
100% (95% CI 52–100) and specificity 75% (95% CI 22–99%)
for samples taken ≥10 days after the onset of symptoms (see
Table 3 upper). The third phase was designed to increase the
precision of the sensitivity estimation. Additional serum
samples from different time points were provided for 43
known RNA (+) patients, 49 in total. The revised sensitivity esti-
mation was 88% (95% CI 75–95) (see Table 3 lower). Using
stored samples from March 2019 the specificity was 100%
(95% CI 91–100).
Discussion and conclusions
This paper provides a robust, real-world assessment of the
potential for a novel and rapid quantitative multiplexed gold
nanoparticle technology detecting antibodies against
SARS-CoV-2 antigens to assist with clinical diagnosis and
decision making. It was performed on a cohort of 74 patients
admitted to hospital early in the pandemic and suspected of
having serious COVID-19 disease. The patient cohort was clini-
cally heterogeneous and characteristic of any scenario in
which a new antibody test must be validated, rather than
being a carefully selected test cohort that may introduce
sources of bias that provide artificially favourable technology
evaluations.
Responses were seen to N, S1 and S2 proteins that were
above derived threshold settings. The highest antibody titre
was against N and so N responses were used to inform setting
the time cut-off classification and to create serological
response profiles for 9 patients. The response profiles showed
the technology was capable of reproducibly detecting quanti-
tative antibody levels over time on different samples. In con-
trast only 18% of samples showed a positive result for all three
antigens (S1, S2 and N) with 50% having N and S2 responses
but only 22% N and S1 responses. The RNA(−) false negative
rate was estimated to be 30% (95% CI 10–46) which is consist-
ent with findings elsewhere16 although sensitivity of PCR
assays may improve with refinement of primers and techno-
logies.17 Serum positivity was defined as having an antibody
response above cut-off against any one of the three antigens,
such that 30% (95% CI 11–48) of initially RNA(−) patients were
identified as serum positive. For samples taken from RNA(+)
patients, the positivity rates were 36% (95% CI 17–54) before
10 days, 77% (95% CI 67–87) between 10 and 20 days and 95%
(95% CI 86–100) after 21 days. The patient-level diagnostic
accuracy relative to RNA(±) after 10 days gave a sensitivity of
88% (95% CI 75–95) and specificity 75% (95% CI 22–99),
although specificity compared with historical controls was
100% (95%CI 91–100).
Our findings are consistent with other published
studies15,16,18–25 up to 9/4/20. The main evaluation approach in
most studies has been to identify patients with confirmed RNA
(+) COVID-19 disease (“cases”) and then compare results with
“controls”, which are either healthy normal patients or less
commonly patients with suspected COVID-19, but in which
disease had been excluded.21,22 Results are then measured in
each group to give estimates of sensitivity from results classifi-
cation in the “cases” and specificity from results classification
in the “controls”. Overall sensitivity of 89% and specificity of
91% found by Li et al.21 was typical of the favourable evalu-
ations. The estimate in the unfavourable evaluation was sensi-
tivity 14% and specificity 92%.16 However, time interval since
onset of symptoms is an obvious variable15 and most studies
thus far have not taken this into account in their accuracy esti-
mates, including that from the unfavourable evaluation,
acknowledging that this can be hard to precisely define from
patient memory and perception of disease symptomatology.
Other challenges which were often not met include recog-
nising the implications of different reference standards, separ-
ating sample and patient levels of analysis and giving
measures of uncertainty. We identified only one study16 which
attempted to look at classification of real-world populations,
where patients had not been specifically pre-separated into
“cases” and “controls”. Cohort heterogeneity is a clear and
important challenge in any clinical setting. We tried to over-
come these challenges in our study, particularly by setting out
on our assessment of this technology by first measuring anti-
body responses in a clinically relevant diverse patient cohort.
However, we had to rely on sensitivity and specificity measured
in cases and controls in subsequent phases to make the most
of the available samples, which is a limitation. Difficulty blind-
ing investigators to the nature of the sample is a further limit-
ation for this component of our study, but was not true where
the initial mixed clinical cohort was investigated. Defining
target condition by a composite reference standard including
clinical profile as well as viral-RNA would have improved our
study too. We would have liked to look in more detail at the
relationship between false positives and false negatives and
Table 3 Patients with samples ≥10 days post symptoms, contingency
tables (threshold three-antigen Boolean classifier)
Viral RNA(+) Viral RNA(−)
Phase 2
S1 or S2 or N ≥ threshold 6 1 7
S1 or S2 or N < threshold 0 3 3
Totals 6 4 10
Phase 3
S1 or S2 or N ≥ threshold 43
S1 or S2 or N < threshold 6
49
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clinical characteristics, but these were small in number and
our ethics did not permit such detailed clinical evaluations.
Concerning the size of the study generally, although the
number of patients and samples were modest, the numbers we
analysed were guided by sample size calculations. We acknowl-
edge that future studies need greater numbers to further
improve precision.
For future research, two-gate designs (the preferred name
for diagnostic case-control accuracy studies) should be
avoided. Two-gate designs calculate sensitivity in those who
definitely have the condition and specificity in those who defi-
nitely do not have the condition, at its extreme completely
healthy people. Although they are a pragmatic approach, often
employed early in the development of a test, they have been
shown to exaggerate the performance of tests26,27 by excluding
borderline cases which will actually make up a high proportion
of patients when the test is actually used in practice. The
problem arising from use of a two-gate design may be regarded
as an extreme form of spectrum bias, a major concern in the
test evaluation.28–30 For these reasons, evaluation is preferred
in a realistic spectrum of disease in population where one
expects the test to be used with a naturally occurring preva-
lence and spectrum of disease.
Since we conducted the literature review to inform our
study, other influential evaluations of antibody tests have
emerged. That by the National COVID Testing Scientific
Advisory Panel in the UK has attracted particular attention.
They concluded that the performance of current lateral flow
immunoassay devices was inadequate for most individual
patient applications. However, we observe that our device is
different to the lateral flow immunoassay devices5 and per-
formed similarly to the novel ELISA tested: sensitivity against
an RT-PCR-confirmed diagnosis of SARS-CoV-2 infection 85%
(95%CI 70–94); specificity vs. pre-pandemic controls 100%
(95%CI 93–100). They used similar methods and sample sizes
to this study. We are currently testing samples from a cohort of
known RNA positive and RNA negative patients to assess
against the sensitivity and specificity requirements set by
regulators.
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